SESSION I
Acute leukemia
BiTes in AML
M. SubkleweIDH inhibitors
E.M. SteinCAR-T cells for adult ALL
M. RuellaTargeting CD47 by monoclonal antibody
D.A. SallmanHDM2 inhibitor
E.M. SteinInotuzumab versus Blinatumomab in ALL
M.S. ToppFLT3 inhibitors
A.E. PerlSESSION II
Hodgkin’s lymphoma
Anti-PD1: Nivolumab and Pembrolizumab
S.M. AnsellCamidanlumab tesirine
G. CollinsAFM13
S.M. AnsellCAR-T
C.A. RamosLectures
Siltuximab
F. van RheeRituximab biosimilars
W. JurczakRavulizumab: the new frontier in PNH therapy
W. BarcelliniMoxetumomab pasudotox
R.J. KreitmanSESSION III
Chronic myeloid leukemia
Ponatinib
G. RostiBosutinib
V. Garcia-GutierrezNilotinib, the correct dose
M. BonifacioSESSION IV
Classical Ph1-neg myeloproliferative neoplasms
Ruxolitinib in polycitemia
A.M. VannucchiNew drugs in myelofibrosis
F. PassamontiTransplant in myelofibrosis: when and how
N.M. KroegerSESSION V
Non-Hodgkin’s lymphoma (I)
Glofitamab
DickinsonMosunetuzumab
E.L. BuddeOdronextamab
M.S. ToppPolatuzumab vedotin
L. SehnLoncastuximab tesirine
P.F. CaimiSESSION VI
Non-Hodgkin’s lymphoma (II)
Zilovertamab
M. WangPirtobrutinib
M. WangSelinexor
J. KuruvillaValemetostat
F. FossSESSION VII
Non-Hodgkin’s lymphoma - PI3K inhibitors (III)
Umbralisib
E. MarchiCopanlisib
M.J. MatasarZandelisib
A.D. ZelenetzLecture
Donor-derived CAR-T cells
F. LockeSESSION VIII
Chronic Lymphocitic Leukemia
Idelalisib
A.D. ZelenetzPirtobrutinib
A.R. MatoDuvelisib
A.R. MatoSESSION IX
Multiple myeloma